IN THIS MONTH'S ISSUE:
February 2017

Mood Stabilizers during Pregnancy: Clinical Updates
Based on current data of in utero exposure to mood stabilizers, valproic acid (Depakene, Depakote, and others) and carbamazepine (Tegretol and others) present the greatest risk for adverse long-term neurobehavioral outcomes, whereas lithium and lamotrigine (Lamictal and others) so far appear to be safe. Antipsychotics have not been adequately studied.

Ongoing Treatment for BDD
Of patients with body dysmorphic disorder who respond to initial treatment with selective serotonin reuptake inhibitors (SSRIs), those who are continued on SSRI treatment for 6 months show greater improvement and longer time to relapse than those switched to placebo.

In Brief
FDA Removes Black Box Warning for Smoking Cessation Drugs Varenicline and Bupropion; Low Levels of Brain-Derived Neurotrophic Factor Decrease Depressed Patients Response to Chemotherapy

Antihypertensives and the Risk of Mood Disorders
In a Scottish retrospective study, patients who took angiotensin antagonist antihypertensive medications had a lower risk of being admitted to the hospital for a mood disorder than those who did not.

Register for FREE Online Access

Please fill in the information requested below to start your free online subscription! All fields marked with a red asterisk (*) are required.

Your Contact Information


If you do not live in the United States or Canada, please select "none" for state.
  
Login Information

(Your email address is your user name)
Residency Director Information
(For resident status verification)
  
Residency Information
 
* denotes required fields.